Literature DB >> 25165181

A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Niek F Casteleijn1, Folkert W Visser1, Joost P H Drenth2, Tom J G Gevers2, Gerbrand J Groen3, Marie C Hogan4, Ron T Gansevoort1.   

Abstract

Chronic pain, defined as pain existing for >4-6 weeks, affects >60% of patients with autosomal-dominant polycystic disease (ADPKD). It can have various causes, indirectly or directly related to the increase in kidney and liver volume in these patients. Chronic pain in ADPKD patients is often severe, impacting physical activity and social relationships, and frequently difficult to manage. This review provides an overview of pathophysiological mechanisms that can lead to pain and discusses the sensory innervation of the kidneys and the upper abdominal organs, including the liver. In addition, the results of a systematic literature search of ADPKD-specific treatment options are presented. Based on pathophysiological knowledge and evidence derived from the literature an argumentative stepwise approach for effective management of chronic pain in ADPKD is proposed.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  ADPKD; management; pain; polycystic kidney disease; polycystic liver disease

Mesh:

Year:  2014        PMID: 25165181      PMCID: PMC4217572          DOI: 10.1093/ndt/gfu073

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  101 in total

1.  Laparoscopic renal denervation for intractable ADPKD-related pain.

Authors:  J F Valente; D R Dreyer; M A Breda; W M Bennett
Journal:  Nephrol Dial Transplant       Date:  2001-01       Impact factor: 5.992

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

3.  Management of chronic pain in a patient with autosomal dominant polycystic kidney disease by sequential celiac plexus blockade, radiofrequency ablation, and spinal cord stimulation.

Authors:  Nathaniel Walsh; Jose E Sarria
Journal:  Am J Kidney Dis       Date:  2012-02-22       Impact factor: 8.860

4.  Laparoscopic bilateral synchronous nephrectomy for autosomal dominant polycystic kidney disease: the initial experience.

Authors:  I S Gill; J H Kaouk; M G Hobart; G T Sung; D K Schweizer; W E Braun
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

Review 5.  Systematic review: the pathophysiology and management of polycystic liver disease.

Authors:  F Temmerman; L Missiaen; B Bammens; W Laleman; D Cassiman; C Verslype; J van Pelt; F Nevens
Journal:  Aliment Pharmacol Ther       Date:  2011-07-26       Impact factor: 8.171

6.  [Percutaneous drainage of benign nonparasitic liver cysts].

Authors:  A A Tanis; P A Rosekrans; R H Wiggers; R J Ouwendijk
Journal:  Ned Tijdschr Geneeskd       Date:  1994-04-23

7.  Percutaneous aspiration and ethanolamine oleate sclerotherapy for sustained resolution of symptomatic polycystic liver disease: an initial experience.

Authors:  Ryosuke Nakaoka; Kunal Das; Masatoshi Kudo; Hobyung Chung; Tatsuo Innoue
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

8.  One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease.

Authors:  Hannes Philipp Neeff; Przemyslaw Pisarski; Dietlind Tittelbach-Helmrich; Konstantin Karajanev; Hartmut P H Neumann; Ulrich Theodor Hopt; Oliver Drognitz
Journal:  Nephrol Dial Transplant       Date:  2012-10-04       Impact factor: 5.992

9.  Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

Authors:  Anna Caroli; Norberto Perico; Annalisa Perna; Luca Antiga; Paolo Brambilla; Antonio Pisani; Bianca Visciano; Massimo Imbriaco; Piergiorgio Messa; Roberta Cerutti; Mauro Dugo; Luca Cancian; Erasmo Buongiorno; Antonio De Pascalis; Flavio Gaspari; Fabiola Carrara; Nadia Rubis; Silvia Prandini; Andrea Remuzzi; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Lancet       Date:  2013-08-21       Impact factor: 79.321

10.  Management of nephrolithiasis in autosomal dominant polycystic kidney disease - A single center experience.

Authors:  Ramen Baishya; Divya R Dhawan; Abraham Kurien; Arvind Ganpule; Ravindra B Sabnis; Mahesh R Desai
Journal:  Urol Ann       Date:  2012-01
View more
  10 in total

1.  Long-term functional results of aspiration and sclerotherapy with ethanol in patients with autosomal dominant polycystic kidney disease: a non-randomized pilot clinical study.

Authors:  Eyüp Veli Küçük; Ahmet Tahra; Ahmet Bindayi; Ferhat Yakup Suçeken; Fikret Fatih Önol; Uğur Boylu
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

2.  Nephrectomy in patients with autosomal dominant polycystic kidney disease, does size matter?

Authors:  Niek F Casteleijn; Ron T Gansevoort; Anna M Leliveld
Journal:  World J Urol       Date:  2016-02-24       Impact factor: 4.226

Review 3.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

4.  Quest for the Cure: Testing the Old and New to Prevent Progression of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Godela Brosnahan
Journal:  Kidney Med       Date:  2019-10-31

Review 5.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

Review 6.  Tailoring the 'Perfect Fit' for Renal Transplant Recipients with End-stage Polycystic Kidney Disease: Indications and Timing of Native Nephrectomy.

Authors:  Chrysoula Argyrou; Demetrios Moris; Spyridon Vernadakis
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 7.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

8.  Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

Authors:  Niek F Casteleijn; Jaime D Blais; Arlene B Chapman; Frank S Czerwiec; Olivier Devuyst; Eiji Higashihara; Anna M Leliveld; John Ouyang; Ronald D Perrone; Vicente E Torres; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2016-11-14       Impact factor: 8.860

9.  Development of Glycerol-Rose Bengal-Polidocanol (GRP) foam for enhanced sclerosis of a cyst for cystic diseases.

Authors:  Soohyun Jeong; Sujin Kim; Youngjoo Choi; Han Na Jung; Kangwon Lee; Min Hee Park
Journal:  PLoS One       Date:  2021-01-05       Impact factor: 3.240

10.  Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease.

Authors:  Ragada El-Damanawi; Michael Lee; Tess Harris; Laura B Cowley; Ingrid Scholtes; Simon Bond; Richard N Sandford; Ian B Wilkinson; Niek F Casteleijn; Marie C Hogan; Fiona E Karet Frankl; Thomas F Hiemstra
Journal:  Clin Kidney J       Date:  2021-02-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.